Meta-analysis of statin therapy in maintenance dialysis patients

References

• Paraskevas KI, Kotsikoris I, Koupidis SA, Tzovaras AA, Mikhailidis DP. Cardiovascular events in chronic dialysis patients: Emphasizing the importance of vascular disease prevention. Int Urol Nephrol. 2010;42:999–1006
   PubMed Web of Science ®Google Scholar
• Robinson JG. Starting primary prevention earlier with statins. Am J Cardiol. 2014;114:1437–1442
   PubMed Web of Science ®Google Scholar
• Green D, Ritchie JP, Kalra PA. Meta-analysis of lipid-lowering therapy in maintenance dialysis patients. Nephron Clin Pract. 2013;124:209–217
   PubMed Web of Science ®Google Scholar
• Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887–1893
   PubMed Web of Science ®Google Scholar
• Seliger SL, Stehman-Breen CO. Are HMG-CoA reductase inhibitors underutilized in dialysis patients? Semin Dialysis. 2003;16:179–185
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet. 2011;377:2181–2192
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Engl J Med. 2005;353:238–248
   PubMed Web of Science ®Google Scholar
• Fellstroem BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New Engl J Med. 2009;360:1395–1407
   PubMed Web of Science ®Google Scholar
• He JF, Wu J, He M, et al. Effect of atorvastatin on the levels of serum homocysteine and carotid intima-media thickness in patients with continuous ambulatory peritoneal dialysis. MMJC. 2012;14:4–6
   Google Scholar
• Yang F, Zhong B, Wang N, Jia HY, Li L. Effects of pravastatin on arterial elasticity in hemodialysis patients with type 2 diabetes. Chin J Blood Purif. 2006;5:137–140
   Google Scholar
• Cui Y, Yang J, Ju L, Ma PL, Li JH, Xie CY. Protective effection of statin therapy in CAPD Patients. Modern J Integr Tradit Chin Western Med. 2011;20:1103–1104
   Google Scholar
• Li KL, Xiong KL, Li ZH, et al. Protective effection of atorvastatin on cardiovascular in maintenance hemodialysis patients. Chin J Arterioscler. 2013;21:57–60
   Google Scholar
• Yao SQ, Hou L. Effect of atorvastatin on CRP and IL-6 in maintenance hemodialysis patients. Chin J Diffic Compl Cas. 2011;10:535–536
   Google Scholar
• Li YM, Xu FF, Chen WS. Effect of different doses of atorvastatin on cytokines and blood pressure during maintenance hemodialysis in patients with chronic renal failure. Zhe Jiang JITCWM. 2009;19:471–473
   Google Scholar
• Pan R. Effect of fluvastatin on CRP and d-dimer in maintenance hemodialysis patients. China Prac Med. 2008;3:53–54
   Google Scholar
• Zhang DS. The effect of fluvastation on microinflammation in patients subjected to maintenance hemodialysis. Guangzhou Med J. 2010;41:25–27
   Google Scholar
• Zheng MT. Effect of fluvastatin on CRP in maintenance hemodialysis patients. Chongqing Med. 2007;36:2012–2013
   Google Scholar
• Zheng XJ. Effect of Simvastatin in improving the micro-inflammatory state of patients treated with maintenance hemodialysis and its action mechanism. China Modern Doctor. 2012;50:52–54
   Google Scholar
• Jin HM, Zhu SJ, Shen GY. Effects of simvastatin on microinflammation and coagulation in hemodialysis patients. Chin J Blood Purif. 2005;4:437–439
   Google Scholar
• He P. The effect of different dose of simvastatin on microinflammation in maintenance hemodialysis patients. J Huaihai Med. 2009;27:538–539
   Google Scholar
• Zhang XD, Li H, Song J, Shi LH, Li Y. Study on the effect of Simvastatin on serum IL-6, IL-8, and TNF-α in maintenance hemodialysis patients. Acta Acad Med CPAF. 2011;20:337–339
   Google Scholar
• Zhang ZL, Wang YR. The effect of simvastatin on microinflammation in patients subjected to maintenance hemodialysis. Modern Prev Med. 2011;38:773–776
   Google Scholar
• Hu FF. The effect of simvastatin on microinflammation in maintenance hemodialysis patients. Clin Med. 2011;31:68–69
   Google Scholar
• Diepeveen SHA, Verhoeven G, Van der Palen J, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: A randomised-controlled trial. J Int Med. 2005;257:438–445
   PubMed Web of Science ®Google Scholar
• Kishimoto N, Hayashi T, Sakuma I, et al. A hydroxymethylglutaryl coenzyme a reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis. Int J Cardiol. 2010;145:21–26
   PubMed Web of Science ®Google Scholar
• Doh FM, Chang T-I, Koo HM, et al. The effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis. Cardiovasc Drugs Ther. 2012;26:501–509
   PubMed Web of Science ®Google Scholar
• Boaz M, Matas Z, Biro A, et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis. 1999;34:438–444
   PubMed Web of Science ®Google Scholar
• Wanner C, Tonelli M, Kidney Disease Improving Global Outcomes. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303--1309
   Google Scholar
• Ma KW, Greene EL, Raij L. Cardiovascular risk-factors in chronic-renal-failure and hemodialysis populations. Am J Kidney Dis. 1992;19:505–513
   PubMed Web of Science ®Google Scholar
• Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y, Japanese Soc Dialysis T. Elevated non-high-density lipoprotein cholesterol (Non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:1112–1120
   PubMed Web of Science ®Google Scholar
• Shoji T. Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients. Clin Exp Nephrol. 2014;18:257–260
   PubMed Web of Science ®Google Scholar
• Maerz W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6:1316–1325
   PubMed Web of Science ®Google Scholar
• Zsom L, Zsom M, Fulop T, et al. Correlation of treatment time and ultrafiltration rate with serum albumin and c-reactive protein levels in patients with end-stage kidney disease receiving chronic maintenance hemodialysis: A cross-sectional study. Blood Purif. 2010;30:8–15
   PubMed Web of Science ®Google Scholar
• Soriano S, Gonzalez L, Martin-Malo A, Rodriguez M, Aljama P. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3–5 patients. Clin Nephrol. 2007;67:352–357
   PubMed Web of Science ®Google Scholar
• Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2013;(9):CD004289
   PubMedGoogle Scholar